Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62015CN0700

    Case C-700/15: Request for a preliminary ruling from the Vrhovno sodišče Republike Slovenije (Slovenia) lodged on 31 December 2015 — LEK Farmacevtska Družba d.d. v Republic of Slovenia

    IO C 111, 29.3.2016, p. 6–7 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    29.3.2016   

    EN

    Official Journal of the European Union

    C 111/6

    Request for a preliminary ruling from the Vrhovno sodišče Republike Slovenije (Slovenia) lodged on 31 December 2015 — LEK Farmacevtska Družba d.d. v Republic of Slovenia

    (Case C-700/15)

    (2016/C 111/08)

    Language of the case: Slovenian

    Referring court

    Vrhovno sodišče Republike Slovenije

    Parties to the main proceedings

    Appellant: LEK Farmacevtska Družba d.d.

    Respondent: Republic of Slovenia

    Questions referred

    1.

    May the provisions of Chapter 30 of the CN be interpreted as meaning that a product, whose main component is an active ingredient (probiotic bacteria) contained in food supplements classified under tariff heading 2106 90 98 CN, is not to be classified in that chapter?

    2.

    For a product to be classified in Chapter 30 of the CN, is it sufficient that the manufacturer presents that product, which contains an active ingredient having beneficial effects on health in general which is often found in food supplements, as a medicinal product, and markets and sells it as such?

    3.

    In the light of the evolution of EU law regulating the market for medicinal products, must the concept of ‘clearly defined therapeutic or prophylactic characteristics’ which, according to the settled case-law of the Court of Justice of the European Union, is a condition for classification in Chapter 30, be interpreted as corresponding to the definition of medicinal product within the meaning of the provisions of EU law relating to medicinal products for human use?
    Top